Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.

Gut - 1 May 2012

Welsch Christoph, Jesudian Arun, Zeuzem Stefan, Jacobson Ira

Abstract excerpt

Until recently, the standard of care (SOC) for patients with chronic hepatitis C virus (HCV) infection has consisted of a combination of pegylated interferon-α [corrected] plus ribavirin, administered for 24- to 48-weeks depending on the HCV genotype. The sustained virologic response rate for this SOC has been only about 50% in patients infected with genotype 1 HCV, the most prevalent genotype in Europe and North...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Oligopeptides

Share to Proline

Share to Serine Proteinase Inhibitors

Source

Identifiers

PMID: 22504918
DOI: 10.1136/gutjnl-2012-302144

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.PMID 22504918Read ↗

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Direct-acting antivirals: the endgame for hepatitis C?Semantic proximity Read ↗

Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.Semantic proximity Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Advances in hepatitis C therapies.Semantic proximity Read ↗

New treatments for chronic hepatitis C virus infection.Semantic proximity Read ↗

What does the pharmacological future of treating chronic hepatitis C look like?Semantic proximity Read ↗

Drugs in development for chronic hepatitis C: a promising future.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.